Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
» Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Submitted by
admin
on July 11, 2016 - 9:15am
Source:
Fierce Pharma
News Tags:
diabetes
Novo Nordisk
Eli Lilly
GLP-1 agonist
Victoza
Trulicity
Headline:
Diabetes sales rocket toward $60B, with Novo and Lilly's GLP-1s first in line for growth
Do Not Allow Advertisers to Use My Personal information
